SABRA MAZIN 4

What Happened

• Sabra Mazin, Chief Operating Officer of ClearPoint Neuro (CLPT), was granted 36,818 restricted stock units (RSUs) on February 17, 2026. The award is reported as a derivative grant at $0.00 per unit (no immediate cash value).

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (accession 0001193125-26-059398).
• Grant: 36,818 restricted stock units (RSUs), acquisition code A; reported price $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU represents a contingent right to one share of CLPT common stock. F2 — vesting: 20% on Feb 17, 2027; 40% on Feb 17, 2028; 40% on Feb 17, 2029.
• Timeliness: Filing dated Feb 19, 2026; within the typical two-business-day Form 4 reporting window.

Context

• These RSUs are compensation awards that convert into common stock only if and when they vest per the schedule above; they are not an open-market purchase or sale. Such grants are a non-cash form of pay/retention and do not by themselves indicate insider buying or selling intent.